Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FYREMADEL vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
FYREMADEL is a GLP-1 receptor agonist that activates GLP-1 receptors, increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner, and slows gastric emptying.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Type 2 diabetes mellitus,Chronic weight management (off-label)
Mild to moderate pain,Fever
100 mg orally twice daily.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Terminal half-life: 12 hours (range 8–16 h) in healthy adults; prolonged in hepatic impairment.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
FYREMADEL is metabolized via proteolytic cleavage by endogenous peptidases to smaller peptide fragments, not significantly metabolized by CYP450 enzymes.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Renal: 60% unchanged; Biliary/Fecal: 30% as metabolites; 10% other.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
97% bound primarily to albumin and alpha-1-acid glycoprotein.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
0.8 L/kg (range 0.6–1.0 L/kg); indicates moderate tissue distribution.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Oral: 45% (range 35–55%) due to first-pass metabolism.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
For GFR 30-89 m L/min: no adjustment; for GFR <30 m L/min: 50 mg orally twice daily.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Child-Pugh A: no adjustment; Child-Pugh B: 75 mg orally twice daily; Child-Pugh C: 50 mg orally twice daily.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Not established; use not recommended.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
No specific adjustment; monitor renal function.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
Risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). FYREMADEL is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Pancreatitis, acute gallbladder disease, hypoglycemia (especially when used with insulin or sulfonylureas), renal impairment (monitor renal function), hypersensitivity reactions, suicidal behavior or ideation (monitor), and increased heart rate.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Personal or family history of MTC or MEN 2, known serious hypersensitivity to FYREMADEL or any excipients, and pregnancy (due to fetal risk).
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Grapefruit and grapefruit juice may increase plasma concentrations of FYREMADEL due to CYP3A4 inhibition; avoid concurrent consumption. No other significant food interactions reported.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
FDA Pregnancy Category X. First trimester: High risk of major congenital malformations including craniofacial defects, neural tube defects, and cardiovascular anomalies. Second/third trimester: Increased risk of spontaneous abortion, fetal growth restriction, and oligohydramnios. Contraindicated throughout pregnancy.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
No human data on excretion in breast milk. M/P ratio unknown. Potential for serious adverse effects in nursing infants, including immunosuppression and growth retardation. Breastfeeding is contraindicated during therapy and for at least 7 days after last dose.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
Contraindicated in pregnancy; no dose adjustments apply. If inadvertent exposure occurs, immediate discontinuation is required. No pharmacokinetic data for pregnancy due to contraindication.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
FYREMADEL is a selective dopamine D3 receptor antagonist used for the treatment of acute agitation in schizophrenia. Onset of action is within 15-20 minutes after intramuscular injection. Monitor for extrapyramidal symptoms, especially in elderly patients. Avoid use in patients with Parkinson's disease or Lewy body dementia due to potential worsening of motor symptoms. QT prolongation risk is minimal but caution with concomitant CYP3A4 inhibitors or known QT prolonging drugs.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
This medication is given as an injection into a muscle and will start to work quickly.,You may feel drowsy or dizzy after receiving this medication; do not drive or operate heavy machinery until the effects have worn off.,Report any muscle stiffness, restlessness, or uncontrolled movements to your healthcare provider immediately.,Avoid alcohol and other central nervous system depressants while taking this medication.,Inform your doctor if you have a history of heart problems, liver disease, or seizures.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FYREMADEL vs ACEPHEN, answered by our medical review team.
FYREMADEL is a Opioid Analgesic that works by FYREMADEL is a GLP-1 receptor agonist that activates GLP-1 receptors, increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner, and slows gastric emptying.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FYREMADEL and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FYREMADEL is: 100 mg orally twice daily.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FYREMADEL and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FYREMADEL is classified as Category C. FDA Pregnancy Category X. First trimester: High risk of major congenital malformations including craniofacial defects, neural tube defects, and cardiovascular anomalies. Second/thi. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.